Probabilistic results: cost-effectiveness (C-E) analysis of management of 100 VL suspects (L-AmB at market price)
| Strategy (diagnosis +treatment) | Cost per 100 suspect VL cases (US$) | Effectiveness (E) per 100 suspect VL cases | C/E ratio | Incremental C/E (ICER) | ||
| Cost (C)±SE | Incremental cost | Deaths±SE | Deaths averted | |||
| D (RDT + SB) | 66 467.35±1088.61 | 5.01±0.03 | 669.70 | |||
| A (BM + SB)* | 76 736.47±1197.66 | 10 269.12 | 5.22±0.03 | −0.21 | 809.61 | Dominated |
| F (RDT + 2-day L-AmB) | 82 478.82±394.81 | 5742.34 | 0.29±0.00 | 4.93 | 827.17 | 1165.00 |
| C (BM + 2-day L-AmB) | 92 854.82±556.84 | 10 376.00 | 0.39±0.00 | −0.10 | 932.21 | Dominated |
| E (RDT + 6-day L-AmB) | 120 740.81±592.47 | 27 885.99 | 1.10±0.01 | −0.70 | 1220.80 | Dominated |
| B (BM + 6-day L-AmB) | 131 035.37±719.90 | 10 294.56 | 1.29±0.01 | −0.19 | 1327.48 | Dominated |
*Current practices in Morocco.
Note: Strategies sorted by cost. Each strategy is compared with the one immediately above.
BM, bone marrow; ICER, incremental cost-effectiveness ratio; L-AmB,liposomal amphotericin B; RDT,rapid diagnostic test; SB: meglumine antimoniate; VL, visceral leishmaniasis.